Income Statement
PHARMACYTE BIOTECH, INC.
PMCB
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Apr 30, 2025 2025 FY | Apr 30, 2024 2024 FY | Apr 30, 2023 2023 FY | Apr 30, 2022 2022 FY | Apr 30, 2021 2021 FY | Apr 30, 2020 2020 FY | Apr 30, 2019 2019 FY | Apr 30, 2018 2018 FY | Apr 30, 2017 2017 FY | Apr 30, 2016 2016 FY | Apr 30, 2015 2015 FY | Apr 30, 2014 2014 FY | Apr 30, 2013 2013 FY | Apr 30, 2012 2012 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.07 |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
|
Gross Profit
|
- | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
|
Operating Expenses
|
4.38 | 8.52 | 6.46 | 4.39 | 3.62 | 3.83 | 4.10 | 6.98 | 4.44 | 6.07 | 13.70 | 18.98 | 1.69 | 2.00 |
|
Research & Development
|
0.44 | 0.41 | 0.47 | 0.69 | 0.92 | 0.30 | 0.46 | 2.00 | 1.18 | 1.41 | 3.48 | - | - | - |
|
Selling, General & Administrative
|
3.94 | 2.12 | 1.11 | 1.09 | 0.42 | 1.16 | 1.38 | 1.82 | 0.74 | 2.29 | 2.60 | 2.24 | 0.62 | 0.42 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-4.38 | -8.52 | -6.46 | -4.39 | -3.62 | -3.83 | -4.10 | -6.98 | -4.44 | -6.07 | -13.70 | -18.98 | -1.68 | -1.95 |
|
Non-Operating Income
|
35.03 | 8.85 | 2.14 | 0.15 | - | - | - | - | - | - | - | - | 0.09 | - |
|
Interest Income
|
1.42 | 3.40 | 1.94 | 0.16 | - | - | - | - | - | - | - | - | - | - |
|
Interest Expense
|
- | - | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.11 | 0.24 |
|
Other Non-Op Income / Expense
|
0.00 | 0.19 | 0.20 | - | 0.07 | 0.00 | 0.03 | 0.15 | 0.00 | 0.01 | 2.84 | -8.27 | - | - |
|
Income Before Tax
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Income Tax Expense
|
0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
30.66 | 0.33 | -4.32 | -4.24 | 3.55 | 3.83 | -4.07 | -6.83 | 0.00 | -6.06 | -10.85 | -27.25 | -1.60 | -1.90 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Apr 30, 2025 2025 FY | Apr 30, 2024 2024 FY | Apr 30, 2023 2023 FY | Apr 30, 2022 2022 FY | Apr 30, 2021 2021 FY | Apr 30, 2020 2020 FY | Apr 30, 2019 2019 FY | Apr 30, 2018 2018 FY | Apr 30, 2017 2017 FY | Apr 30, 2016 2016 FY | Apr 30, 2015 2015 FY | Apr 30, 2014 2014 FY | Apr 30, 2013 2013 FY | Apr 30, 2012 2012 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-4.38 | -8.52 | -6.46 | -4.39 | -3.62 | -3.83 | -4.10 | -6.98 | -4.44 | -6.07 | -13.70 | -18.98 | -1.68 | -1.92 |
|
Earnings Per Share (Basic)
|
3.19 | -1.80 | -0.22 | -0.27 | - | - | - | - | - | - | - | -0.05 | 0.00 | 0.01 |
|
Diluted EPS
|
3.19 | -1.80 | -0.22 | -0.27 | - | - | - | - | - | - | - | - | - | - |
|
Weighted Average Shares
|
7.33 | 9.58 | 19.49 | 15.52 | 1.45 | 1,355.72 | 1,100.10 | 968.64 | 845.31 | 752.40 | 704.33 | 583.22 | 440.95 | 374.76 |
|
Diluted Weighted Avg Shares
|
7.33 | 9.58 | 19.49 | 15.52 | 1.45 | 1,355.72 | 1,100.10 | 968.64 | 845.31 | 752.40 | 704.33 | - | - | - |
|
Comprehensive Income
|
30.66 | 0.33 | -4.32 | -4.23 | -3.55 | -3.83 | -4.08 | -6.84 | -4.44 | -6.06 | -10.85 | - | - | - |